Spero Therapeutics, Inc.

Clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multidrug-resistant bacterial infections. Developer of tebipenem HBr (tebipenem pivoxil), exclusively licensed to GSK for most territories with certain development responsibilities sub-licensed back to Spero.